In a nutshell This study investigated the safety, effectiveness, and side effect profile of chemotherapy given before surgery for the treatment of patients with locally advanced colon cancer (LACC). The data showed that this treatment was safe and effective with manageable side effects for these patients. Some background Colorectal cancer (CRC) is one...
Read More
In a nutshell The aim of this study was to evaluate the impact of adding oxaliplatin (Eloxatin) to the chemotherapy regimen tegafur uracil (UFT)/leucovorin (LV; folinic acid) for patients that had surgery for colorectal cancer (CRC). The study found that the addition of oxaliplatin to UFT/LV improved patient outcomes. Some background CRC can...
Read More
In a nutshell This study evaluated whether chemoradiotherapy (CRT) before surgery improves the outcomes of patients with stage II-III colorectal cancer (CRC). The study found that CRT before surgery may not be needed in certain patients with low-risk disease. Some background CRC is the third most common cancer worldwide. The standard therapy for...
Read More
In a nutshell This trial looked at the length of adjuvant chemotherapy (AC; chemotherapy after surgery) for patients with stage III colon cancer. The authors found that 3 months of AC resulted in similar survival with reduced levels of toxicity, and cost compared to 6 months. Some background AC has been standard care for patients with...
Read More
In a nutshell This study compared 3 and 6 months of oxaliplatin (Eloxatin)-based chemotherapy in stage 2 colon cancer. Researchers suggested that the 3-month treatment might be a good and safer option for these patients. Some background Colorectal cancer is the third most common cancer diagnosed in both men and women in the US. Chemotherapy after...
Read More
In a nutshell This study investigated the occurrence of cachexia (CX; weight loss and muscle wasting) in patients with advanced colorectal cancer after first-line therapy. Researchers suggested that CX is present in half of these patients within 24 weeks after starting first-line therapy. Some background Colorectal cancer is the third most common...
Read More
In a nutshell This study investigated whether chemotherapy plus bevacizumab (Avastin) before and after or after surgery improves the survival of patients with colorectal cancer (CRC) and operable liver metastasis (LM; cancer spread to the liver). Researchers suggested that chemotherapy and bevacizumab before and after...
Read More
In a nutshell This study investigated the effectiveness of cetuximab (Erbitux) in combination with chemotherapy for the treatment of advanced colorectal cancer (CRC). Researchers suggested that this combined treatment improves the outcomes of patients with CRC. Some background CRC is one of the most common cancers worldwide. Around 15 to 25% of...
Read More
In a nutshell This study compared two different chemotherapy treatments in metastatic colorectal cancer (mCRC; spread to other parts of the body). Researchers suggested that 24-hour infused irinotecan (Camptosar) plus oral S-1 (Teysuno) chemotherapy and bevacizumab (Avastin) is well tolerated and associated with improved outcomes. Some background...
Read More
In a nutshell This study investigated the effectiveness of the combined treatment with cytokine-induced killer cell (CIKC) immunotherapy and chemotherapy after surgery in colorectal cancer. Researchers suggested that this therapy improves treatment outcomes in patients with colorectal cancer. Some background Colorectal cancer is one of the most common...
Read More
In a nutshell This study investigated the effectiveness and safety of bevacizumab (Avastin) combined with chemotherapy in elderly patients with advanced colorectal cancer. Researchers suggested that this therapy might be associated with improved outcomes in fit older patients. Some background Colorectal cancer is the third most common cancer...
Read More
In a nutshell This study compared two different types of chemotherapy for patients with metastatic (spread to other parts of the body) colorectal cancer (mCRC). Researchers suggested that FOLFOXIRI plus bevacizumab (Avastin) is associated with better outcomes in these patients. Some background Colorectal cancer is the third most common cancer...
Read More
